← Human Trials & Peer-Reviewed Studies
A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study
Plain-language guide to PMID 20713345 (2011): open-label randomized controlled trial study of Insulin Glargine and Insulin Aspart in 2 patients.
Key Facts
- PMID
- 20713345
- Journal
- Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
- Year
- 2011
- Study type
- Randomized Controlled Trial
- Authors
- Ligthelm RJ et al. (4 authors)
- DOI
- 10.4158/EP10079.OR
- Registered trial
- NCT00097877
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Insulin Glargine and Insulin Aspart, published as a randomized controlled trial.
Who Took Part
The abstract describes 2 patients taking part.
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
In a 24-week, open-label, parallel-group trial, type 2 diabetic patients who were not maintaining glycemic control on basal insulin (glargine or neutral protamine Hagedorn) + oral antidiabetic drugs were randomly assigned to twice-daily BIAsp 30 + metformin or once-daily glargine + metformin + secretagogues (secretagogues were discontinued in the BIAsp 30 arm).
How the Study Was Run
The researchers set it up as a randomized, open-label and parallel-group study.
Random assignment meant chance, not the researchers, decided who got Insulin Glargine and who got the comparison, which limits bias.
Being open-label, the Insulin Glargine study did not mask who received what.
The Insulin Glargine group and the comparison group ran side by side rather than switching.
What Was Measured
Topics PubMed links to this paper include Biphasic Insulins, Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents, Insulin and Insulin Aspart.
What This Means in Plain Language
The paper is a randomized, open-label and parallel-group study of Insulin Glargine and Insulin Aspart in 2 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2011 (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists), a journal based in United States.
More context: the Insulin Glargine compound page and the Insulin Aspart compound page.
Our Notes on the Compounds
Insulin Glargine: A long-acting insulin analog given once daily; brands include Lantus, Toujeo, Basaglar and Semglee.
Insulin Aspart: A rapid-acting mealtime insulin analog; brands include NovoLog, NovoRapid and Fiasp.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.